Scarica l'app Stockscreener
1.28
1.54%
-0.02
Pre-mercato:
1.30
0.02
+1.56%
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
Lucid Diagnostics Inc (LUCD) receives a Buy rating from Ascendiant Capital Markets - Knox Daily
Behind Lucid Diagnostics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Lucid Diagnostics Inc (LUCD) Shares Rise Despite Market Challenges - The News Heater
Sargent Investment Group LLC Purchases Shares of 541,500 Lucid Diagnostics Inc. (NASDAQ:LUCD) - MarketBeat
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science and Diagnostic Tools Conference - Marketscreener.com
Cancer Prevention Leader Lucid Diagnostics Takes Center Stage at Elite BTIG Healthcare Summit - StockTitan
Lucid Diagnostics Provides Business Update and Second Quarter 20 - GuruFocus.com
Lucid Diagnostics (NASDAQ:LUCD) Stock Price Down 0.5%What's Next? - MarketBeat
Lucid Diagnostics (NASDAQ:LUCD) Stock Price Down 0.5% – Here’s What Happened - Defense World
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - PR Newswire
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Quantisnow
Lucid Diagnostics Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Defense World
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - PR Newswire
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
Lucid Diagnostics' SWOT analysis: stock faces challenges amid market potential - Investing.com
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - Morningstar
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $7.00 at Ascendiant Capital Markets - Defense World
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - The Eastern Progress Online
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 30.6% in November - MarketBeat
Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements - TipRanks
Head-To-Head Review: Lucid Diagnostics (NASDAQ:LUCD) & DIH Holding US (NASDAQ:DHAI) - Defense World
This Pill-Size Diagnostic Seeks to Prevent Thousands of Esophageal Cancer Deaths - MedCity News
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com
Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com
Lucid Diagnostics' SWOT analysis: stock outlook amid reimbursement progress - Investing.com
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - Morningstar
Lucid Diagnostics Announces Agreement for Sale of Senior Secured Convertible Notes - Defense World
Lucid Diagnostics Inc. announced that it expects to receive $21.75 million in funding - Marketscreener.com
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com
Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges - Investing.com Australia
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald - MarketBeat
PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy
Lucid Diagnostics (NASDAQ:LUCD) Provides Business Update and Financial Results - Defense World
Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Lucid Diagnostics reports revenue growth and strategic expansion - Investing.com UK
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
0.38%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):